Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Metastatic Breast Cancer|Advanced Ovarian Cancer|Carboplatin|Paclitaxel
Interventions: DRUG: KU-0059436 (AZD2281)(PARP inhibitor)|DRUG: Carboplatin|DRUG: KU-0059436 (AZD2281)(PARP inhibitor)|DRUG: Paclitaxel|DRUG: KU-0059436 (AZD2281)(PARP inhibitor)|DRUG: Paclitaxel + Carboplatin
Sponsor: AstraZeneca